Ventrio® clinical data

Set-up:

20 participants between 23-72 years old (8 male and 12 female) were advised to take 2 capsules of Ventrio® daily during a period of 4 weeks. No other products (or food) with an influence on the stool were allowed during the entire follow-up period.

Clinical scores (Bristol stool, flatulence, bloating, stomach ache, wellbeing and frequence) were documented daily and stool samples were taken before study start and at week 2 and 4 for metagenomics 16S profiling analysis to assess the gut microbiome.

 Results:

All participants with diarrhea (Bristol score > 4 at day 0) showed significant improvement within 24-48h after Ventrio® intake.

Participants with flatulence showed significant improvement within 24h after Ventrio® intake.

Bloating and stomach ache normalized within 1-2 weeks after Ventrio® intake. In 4 participants an increase in bloating was noticed at week 3 which resolved when reducing the dose to 1 capsule a day. 

Also the daily stool frequency normalized in all patients with hypermotility after Ventrio® intake.

An average net promotor score of 7/10 was noted and 73% of participants with clinical discomfort noticed improvement.

The metagenomics analysis revealed 985 different bacterial species (see example of Sankey visualization below) inthe stool of the 20 participants.

Lactobacillus rhamnosus and plantarum were not detectable before study start and significantly increased in the stool over time after Ventrio® intake.

Detection of Streptococcus species significantly reduced after Ventrio® intake.

Conclusion:

In conclusion, a daily intake of 2 capsules of Ventrio® for 2 weeks resulted in clinical and microbiological improvement in humans with gastro-intestinal discomfort.

For long term use it is advised to reduce the dose to 1 capsule per day after 2 weeks.